AbCellera Biologics Inc. (ABCL)

Market Cap	1.18B
Revenue (ttm)	38.03M
Net Income (ttm)	-146.40M
Shares Out	292.78M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	27.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,199,529
Open	3.920
Previous Close	3.850
Day's Range	3.920 - 4.200
52-Week Range	3.620 - 8.050
Beta	0.36
Analysts	Strong Buy
Price Target	19.00 (+371.46%)
Earnings Date	May 7, 2024

About ABCL

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 586
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL

Analyst Forecast

According to 6 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 371.46% from the latest price.

Price Target

$19.0

(371.46% upside)

Analyst Consensus: Strong Buy